Femme Homme
- | Pays :
- United States
- | Organes : -
- | Spécialités : -
Extrait
The FB-8 study is designed as an open label, single arm, Phase I dose-escalation study evaluating the combination of weekly paclitaxel with neratinib and trastuzumab in women with metastatic, HER2-positive breast cancer. The primary aim of this study is to determine the safety and tolerability of the three-drug combination.
Critère d'inclusion
- Breast Cancer